Top

Medical Oncology

Published in:

Open Access 01-11-2023 | Confusion | Letter to the Editor

Letter to editor: confusions about the role of RNF149 in apoptosis and PI3K/AKT signaling

Authors: Xiaobin Guo, Qian Yang, Hongxin Yang

Published in: Medical Oncology | Issue 11/2023

Excerpt

Dear Editor, …

Zhu J, Tang J, Wu Y, Qiu X, Jin X, Zhang R. RNF149 confers cisplatin resistance in esophageal squamous cell carcinoma via destabilization of PHLPP2 and activating PI3K/AKT signaling. Med Oncol. 2023. https://doi.org/10.1007/s12032-023-02137-z.CrossRefPubMedPubMedCentral

Benedito A, Carneiro, Wafik S, El-Deiry. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020. https://doi.org/10.1038/s41571-020-0341-y.CrossRef

Alberto Martín J, Odajima SL, Hunt P, Dubus S, Ortega M, Malumbres. Mariano Barbacid. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell. 2005. https://doi.org/10.1016/j.ccr.2005.05.006.CrossRefPubMed

Title: Letter to editor: confusions about the role of RNF149 in apoptosis and PI3K/AKT signaling
Authors: Xiaobin Guo
Qian Yang
Hongxin Yang
Publication date: 01-11-2023
Publisher: Springer US
Keyword: Confusion
Published in: Medical Oncology / Issue 11/2023
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-023-02213-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2023

How gallic acid regulates molecular signaling: role in cancer drug resistance

Combretastatin A-4 suppresses the invasive and metastatic behavior of glioma cells and induces apoptosis in them: in-vitro study

Recent advancement in targeted therapy and role of emerging technologies to treat cancer

Are medical oncologists ready for the artificial intelligence revolution? Evaluation of the opinions, knowledge, and experiences of medical oncologists about artificial intelligence technologies

Multitargeted inhibitory effect of Mitoxantrone 2HCl on cervical cancer cell cycle regulatory proteins: a multitargeted docking-based MM\GBSA and MD simulation study

Identification of novel inhibitors from Urtica spp against TNBC targeting JAK2 receptor for breast cancer therapy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials